Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.67 |
| ▸ | MAOA | P21397 | 5/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | SDHA | P31040 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CALML3 | P27482 | 1/20 | 0.67 |
| ▸ | F10 | P00742 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406832 | 1.00 | MAOB (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL2406825 | 1.00 | MAOB (0.67) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6854026 | 0.89 | MAOA (0.53) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL28998570 | 0.85 | MAOB (0.68) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL27801851 | 0.85 | MAOB (0.68) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL2046431 | 0.84 | MAOB (0.46) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7030086 | 0.84 | MAOB (0.61) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3181066 | 0.84 | MAOA (0.60) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6097931 | 0.84 | MAOB (0.48) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3519815 | 0.84 | MAOB (0.48) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2899185-B1 | Processes for preparing linezolid | UNIV INDIANA RES & TECH CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9656973-B2 | Processes for preparing linezolid | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2563781-B1 | PROCESSES FOR PREPARING LINEZOLID | UNIV INDIANA RES & TECH CORP (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160024032-A1 | PROCESSES FOR PREPARING LINEZOLID | UNIV INDIANA RES & TECH CORP (US) | 2016-01-28 | — | — | US | disclosed |
| US-9206141-B2 | Processes for preparing linezolid | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2899185-A1 | Processes for preparing linezolid | Indiana University Research and Technology Corporation (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2563781-A1 | PROCESSES FOR PREPARING LINEZOLID | Indiana University Research and Technology Corporation (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130053557-A1 | PROCESSES FOR PREPARING LINEZOLID | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2011137222-A1 | PROCESSES FOR PREPARING LINEZOLID | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024032-A1 | PROCESSES FOR PREPARING LINEZOLID | CYP2C9, CYP2C19, CYP3A43 | MAOB 1936/4885MAOA 1768/4885PTGS1 3373/4885 |
| US-20130053557-A1 | PROCESSES FOR PREPARING LINEZOLID | CYP2C9, CYP2C19, CYP3A43 | MAOB 1936/4885MAOA 1768/4885PTGS1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.